Getting Off Pegloticase Without Losing What It Fixed
A single patient's tophi have fully resolved after fourteen months of pegloticase. The disagreement is how — and exactly when — to come off a drug that worked, before the antibody risk it's known for catches up with him.
Theo B., a 46-year-old guitarist who plays in a working wedding band most weekends, had reached the point eighteen months ago where tophi in both hands made barre chords genuinely difficult, and a solo he'd played for a decade had started coming out wrong. Fourteen months of pegloticase infusions later, his hands are visibly, functionally clear — the last imaging showed no residual tophus burden at all, and he says he can feel the difference every time he picks up the instrument. He arrives today not with a flare or a complication, but with a question nobody has fully answered for him: how much longer is he supposed to keep doing this.
Pegloticase's own labeling doesn't specify a maximum duration, but real-world practice has settled around limiting courses to roughly six months to two years, driven by the same antibody problem that makes co-therapy necessary in the first place — the longer a patient stays on it, the more cumulative exposure to anti-drug antibodies builds, raising both the risk of a serious infusion reaction and the eventual near-certainty of losing efficacy as those antibodies neutralize the drug faster than it can act. Theo is fourteen months in, tophus-free, and his urate has stayed below 3 mg/dL for the past six infusions in a row — a genuinely good outcome, and also the exact point at which continuing indefinitely stops making obvious sense. What has no established protocol at all is the transition itself: how to overlap or sequence an oral xanthine oxidase inhibitor with the tail end of pegloticase therapy, since restarting pegloticase after a gap once antibodies have already formed carries its own real anaphylaxis risk, which forecloses treating this as a reversible experiment.
A good response, and no map for how to end it
Fourteen months in, tophus-free, urate under 3 for six infusions straight — this is exactly the point real-world duration practice says to start planning the exit, before his antibody exposure keeps climbing for no additional benefit. I'd overlap febuxostat for several weeks before the last infusion, rather than stop cold and hope the oral agent catches up before urate rebounds and a flare follows.
I'd want more of a safety net than that. He never reached target urate on maximized febuxostat or allopurinol before pegloticase was started — that's not ancient history, that's his own documented response. Assuming an XOI will simply hold him now, just because his tophi are gone, skips over the reason we escalated to pegloticase in the first place. I'd want a specific urate threshold set now for when we escalate back — probenecid added, or pegloticase resumed if it's still safe to — rather than finding out only after his number has already climbed.
An overlap window helps with the immediate rebound risk, but it doesn't answer what happens a few months later once pegloticase is fully out of the picture and he's back to the regimen that didn't work for him before.
I want to name something neither of you has: there's no actual protocol data for overlapping these two drugs at end of pegloticase therapy — the timing either of you would pick is a reasonable guess, not a validated approach. I'd rather stop pegloticase cleanly, start febuxostat immediately without trying to engineer a precise overlap, and check urate every two weeks rather than every routine interval until we know where he's actually landing. That gives us real data fast enough to act on either of your contingencies before a flare, rather than betting on an untested overlap schedule.
Agreed: pegloticase stopped, febuxostat started immediately with colchicine prophylaxis, and urate checked every two weeks with a pre-agreed threshold for adding probenecid rather than waiting to see how badly a rebound develops before acting.
Not agreed: whether an overlap window would have been safer than the clean stop that was ultimately chosen. The first rheumatologist still believes overlapping would have reduced the rebound window further; the second rheumatologist's concern about unvalidated timing carried the day given no protocol evidence exists either way. Both agreed the two-week monitoring interval is what actually protects him regardless of which transition method turns out to have been better.